Ehsan Ghorani

About

I am a CRUK Clinician Scientist and Associate Professor in Cancer Immunology at Imperial College London where I am Group Leader in the Division of Cancer. Clinicially, I work as a Consultant Medical Oncologist within the Charing Cross Hospital National Trophoblastic Disease Centre. My research focusses on better understanding T cell immune regulation and novel therapeutic and diagnostic approaches arising from this.

Employment

• Imperial College London Associate Professor in Cancer Immunology
  2023 - Present
• Emory University Postdoctoral Fellow
  2023 - 2023
• Imperial College London Honorary Senior Research Fellow
  2022 - 2022
• University College London Wellcome Trust Clinical Research Fellow
  2017 - 2021
• Imperial College London NIHR Academic Clinical Fellow in Medical Oncology
  2014 - 2022

Education

Education history is unavailable.

Projects & Funding

• Identifying biomarkers to facilitate personalised risk assessment for epithelioid and placental site trophoblastic tumours. Wellbeing of Women
  2025 - 2028
• Development of novel biomarkers of pembrolizumab response in non-small cell lung cancer Lung Cancer Research
  2023 - Present
• REFINE-Lung: A randomised open-label phase III trial of REduced Frequency pembrolizumab ImmuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design. National Institute for Health and Care Research
  2021 - 2028
• Co-evolution of tumour mutational and CD4 T-cell differentiation landscapes Wellcome Trust Ltd
  2017 - 2021
• Deciphering mechanisms of immune dysfunction and immunotherapy sensitivity in gestational trophoblastic neoplasia Cancer Research UK
• AI driven analysis of circulating and tumour infiltrating immune cell morphology to develop novel biomarkers of lung cancer immunotherapy resistance. Imperial College Healthcare NHS Trust

Publications (50)

• Current and future treatments for low-risk gestational trophoblastic neoplasia.
  Annals of oncology : official journal of the European Society for Medical Oncology 2025 DOI: 10.1016/j.annonc.2025.07.018
  +Save
• Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCI…
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 DOI: 10.1200/jco-24-02326
  +Save
• Controversies in malignant ovarian germ cell tumors.
  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025 DOI: 10.1016/j.ijgc.2025.101670
  +Save
• Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study.
  BMJ medicine 2025 DOI: 10.1136/bmjmed-2024-001017
  +Save
• Future Directions for Gestational Trophoblastic Disease.
  Hematology/oncology clinics of North America 2024 DOI: 10.1016/j.hoc.2024.08.019
  +Save
• Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 DOI: 10.1158/1078-0432.ccr-23-1316
  +Save
• What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
  Therapeutic advances in medical oncology 2023 DOI: 10.1177/17588359231210271
  +Save
• Cancer cell-intrinsic mechanisms driving acquired immune tolerance.
  Immunity 2023 DOI: 10.1016/j.immuni.2023.09.004
  +Save
• Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm.
  Gynecologic and obstetric investigation 2023 DOI: 10.1159/000533972
  +Save
• REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.
  The Lancet. Oncology 2023 DOI: 10.1016/s1470-2045(23)00095-5
  +Save
• Novel approaches to managing gestational trophoblastic tumors in the age of immunotherapy.
  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023 DOI: 10.1136/ijgc-2022-003771
  +Save
• Two faces: IL-22 effects prevail over defense against metastasis.
  Immunity 2023 DOI: 10.1016/j.immuni.2022.12.013
  +Save
• REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
  Contemporary clinical trials 2022 DOI: 10.1016/j.cct.2022.107030
  +Save
• Emergency craniotomy: a life-saving procedure as part of multi-modal therapy of GTN.
  Journal of gynecologic oncology 2022 DOI: 10.3802/jgo.2022.33.e52
  +Save
• Sensitive screening of single nucleotide polymorphisms in cell free DNA for diagnosis of gestational tumours.
  NPJ genomic medicine 2022 DOI: 10.1038/s41525-022-00297-x
  +Save
• Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
  Lewis Au, Emine Hatipoglu, Marc Robert de Massy +97 more
  Cancer cell 2021 DOI: 10.1016/j.ccell.2021.10.001
  +Save
• Using DNA sequencing data to quantify T cell fraction and therapy response.
  Robert B. Bentham, Kevin Litchfield, Thomas B.K. Watkins +97 more
  Nature 2021 DOI: 10.1038/s41586-021-03894-5
  +Save
• Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
  The Lancet. Oncology 2021 DOI: 10.1016/s1470-2045(21)00262-x
  +Save
• Progress to international harmonisation of care and future developments.
  Best practice & research. Clinical obstetrics & gynaecology 2021 DOI: 10.1016/j.bpobgyn.2021.05.006
  +Save
• Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate.
  Gynecologic oncology reports 2021 DOI: 10.1016/j.gore.2021.100782
  +Save